BlackRock
CYT

BlackRock’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

BlackRock’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-91,578
Closed -$278K – 5435
2023
Q4 		$278K Buy
91,578
+5,994
+7% +$18.2K ﹤0.01% 4559
2023
Q3 		$243K Sell
85,584
-2,823
-3% -$7.78K ﹤0.01% 4627
2023
Q2 		$230K Buy
88,407
+7,161
+9% +$15K ﹤0.01% 4697
2023
Q1 		$148K Buy
81,246
+1,902
+2% +$3.09K ﹤0.01% 4867
2022
Q4 		$131K Sell
79,344
-117,568
-60% -$189K ﹤0.01% 4963
2022
Q3 		$376K Sell
196,912
-4,592
-2% -$12K ﹤0.01% 4806
2022
Q2 		$601K Sell
201,504
-463,242
-70% -$1.18M ﹤0.01% 4714
2022
Q1 		$2.51M Buy
664,746
+122,324
+23% +$696K ﹤0.01% 4298
2021
Q4 		$6.17M Buy
542,422
+151,023
+39% +$2.3M ﹤0.01% 3904
2021
Q3 		$6.87M Buy
+391,399
New +$7.32M ﹤0.01% 3836

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

BlackRock's CYT Position: Q1 2024 in Review

BlackRock sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 91,578 shares — an estimated $278K sold.

BlackRock first reported a position in CYT in Q3 2021 and held it in 10 quarters. The position peaked at $6.87M in Q3 2021. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • BlackRock reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • BlackRock sold 91,578 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $278K.
  • BlackRock first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q3 2021 and held it in 10 quarters.
  • BlackRock's Cyteir Therapeutics, Inc. Common Stock position peaked at $6.87M in Q3 2021.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on BlackRock's 13F filing for Q1 2024, filed 10 May 2024.